Video
Dr. Jeffrey Jones on Long-Term Outcomes With Ibrutinib in CLL
Author(s):
In Partnership With:
Jeffrey Jones, MD, MPH, assistant professor of Internal Medicine, Division of Hematology, Department of Internal Medicine, Ohio State University Wexner Medical Center, discusses the long-term outcomes associated with ibrutinib (Imbruvica) for the treatment of patients with chronic lymphocytic leukemia (CLL).
Jeffrey Jones, MD, MPH, assistant professor of Internal Medicine, Division of Hematology, Department of Internal Medicine, Ohio State University Wexner Medical Center, discusses the long-term outcomes associated with ibrutinib (Imbruvica) for the treatment of patients with chronic lymphocytic leukemia (CLL).
For chemoimmunotherapy, researchers can estimate the long-term responses patients may or may not have. However, the same cannot be said for ibrutinib, as it is a newer agent in the field, Jones explains. For younger patients receiving ibrutinib, it is important to consider long-term toxicities that have yet to emerge, as well as treatment compliance.
This varies for patients depending on their age, as older patients may need to consider whether they would rather receive ibrutinib for an unprecedented amount of time versus 6 months of chemoimmunotherapy.
